Roadmap / Phases

Phase 1 → Phase 3. Foundation to sovereign scale.

A disciplined three-phase plan that turns scientific platforms into deployed therapies and sovereign biotech infrastructure.

Phase 1 — Foundation. Lock down the core IP across our seven programmes, stand up the U.S. R&D and operational backbone, and complete the first GCC partnership LOIs. Build the omics + AI substrate that every subsequent programme will plug into.

Phase 2 — Clinical Translation. Move the flagship hair-regeneration programme to first-in-human trials, open the GCC rare-disease registry, and stand up bioreactor capacity for liver / organ bioengineering. Secure the first round of sovereign-aligned strategic capital.

Phase 3 — Sovereign Deployment. Localise manufacturing in-region, license platform technologies into clinical / veterinary / longevity markets, expand the women's-health regenerative platform, and graduate the rare-disease registry into a sovereign-scale precision-medicine asset. Ten-year platform-vision target: $325M deployed.

Phase 1

Foundation

Phase 2

Clinical Translation

Phase 3

Sovereign Deployment

$325M

10-Year Vision

10-Year Roadmap · Milestones I — III

From validation to a sovereign biotech hub.

A phased platform plan totaling approximately $325M in long-horizon investment — anchored by the iREY flagship and culminating in regional organ-engineering scale.

Milestone I0 — 3 years